Ann: Appendix 4C & Quarterly Activities Report, page-85

There has been a lot of progress since then.

The company has plenty of funds.
About 3 years worth of funds at current cost/income level —however with increased uptake and income as private insurers ultimately pay for Sozo diagnostics for lymphodema monitoring & detection, the revenue should increase and then the company’s funds last ongoing through years.
By which time a lot more would be happening with renal disease (partnering with large company most likely ) and heart failure and sarcopenia as well.

ImpediMed is priced at an EV right now of barely $60 million, market cap $100 million aud.
With sufficient reserve funds for the next few years.

ImpediMed is income and revenue generating and without doubt not only important fully approved and providing the best simple & only medical diagnostics for fluid definition for detection of lymphedema—but also accurate diagnosis for renal disease status and heart failure and for chemotherapy patients to be accurately assessed prior to treatments.

You have the sad part right but there is nothing bad - it’s just slow & covid has been big factor for hospitals.

There is no reason private insurance payers will now not soon be forced to pay routinely for the diagnostics and end the need for every claim to be pursued for their payment as is currently occurring. Requiring administrative work to receive payment but the centres and hospitals which use Sozo are very happy and Sozo is crucial to diagnosis & care.

Hospital administrations will jump more once one private insurer begins to blanket pay for all.

The main and best cancer clinics everywhere already use Sozo routinely in the US, as also occurs here in Australia and I think New Zealand. ( for lymphedema diagnosis & checking but also increasing to expanded use in hospitals due to the capabilities of Sozo in renal and for sarcopenia assessment also)